# Antiviral Activity of Biocompatible Bionanocatalysts against Rotavirus

## TL;DR

Researchers developed biocompatible nanomaterials that can reduce rotavirus infectivity before and after infection, offering a safe and effective antiviral treatment.

## Contribution

The study introduces biocompatible bionanocatalysts as a novel antiviral strategy with pre- and postinfection efficacy against rotavirus.

## Key findings

- Bionanocatalysts significantly reduced rotavirus infectivity in MA104 cells before viral exposure.
- Postinfection treatment with bionanocatalysts also reduced infectivity, though less effectively.
- The nanomaterials showed no cytotoxicity in uninfected cells, indicating safety and specificity.

## Abstract

Rotavirus
remains a significant cause of gastroenteritis,
especially
in infants and young children, leading to severe dehydration and even
death in resource-limited settings. While vaccines are available,
they offer incomplete protection, and effective antiviral treatments
are lacking. This study investigates the antiviral potential of biocompatible
bionanocatalysts against rotavirus, focusing on both pre- and postinfection
stages. Such structures consist of nanostructured materials composed
of pure or mixed oxides that form a heterogeneous catalyst with a
full dispersion of the active metal, exhibiting potentiated catalytic
properties (compared to common solid acid catalysts) and organic functional
groups that mimic cellular ligands, thus endowing them with biocompatibility
and affinity. Bionanocatalysts were synthesized and characterized,
showing a uniform nanoscale distribution and high surface reactivity.
Tests using the MA104 cell line demonstrated that these structures
could significantly reduce viral infectivity when administered prior
to viral exposure, likely by interacting with viral surface proteins
and degrading the RNA genome. The treatment also reduced infectivity
postinfection, though to a lesser extent. Importantly, the bionanocatalysts
showed no cytotoxicity in uninfected cells, underscoring their safety
and specificity. This research highlights the potential of bionanocatalysts
as a novel antiviral therapy for rotavirus, providing a promising
addition to existing preventive measures, particularly in areas with
limited access to vaccines.